We've upgraded AI Search on TaxTMI with two powerful modes:
1. Basic • Quick overview summary answering your query with references• Category-wise results to explore all relevant documents on TaxTMI
2. Advanced • Includes everything in Basic • Detailed report covering: - Overview Summary - Governing Provisions [Acts, Notifications, Circulars] - Relevant Case Laws - Tariff / Classification / HSN - Expert views from TaxTMI - Practical Guidance with immediate steps and dispute strategy
• Also highlights how each document is relevant to your query, helping you quickly understand key insights without reading the full text.Help Us Improve - by giving the rating with each AI Result:
Tribunal Classifies 'Caloshell' as Medicament, Not Vitamin: Key Factors The Tribunal classified 'caloshell' as a medicament under Chapter Heading 3003.10, overturning the Department's classification as a vitamin under Heading ...
Cases where this provision is explicitly mentioned in the judgment/order text; may not be exhaustive. To view the complete list of cases mentioning this section, Click here.
Provisions expressly mentioned in the judgment/order text.
Tribunal Classifies 'Caloshell' as Medicament, Not Vitamin: Key Factors
The Tribunal classified 'caloshell' as a medicament under Chapter Heading 3003.10, overturning the Department's classification as a vitamin under Heading 2936.00. Despite arguments on therapeutic value, the Tribunal emphasized the product's approval as a drug, intended use for pediatric deficiencies, and previous rulings on similar products. Considering its measured doses, physician prescription requirement, and FDA approval, 'caloshell' was deemed a medicament due to its intended medicinal purpose in treating calcium and vitamin D deficiencies in children, specifically for rickets.
Issues: Classification of product 'caloshell' under Chapter Heading 3003.10 or 2936.00
Analysis: 1. The appellant claimed that 'caloshell' should be classified as a medicament under Chapter Heading 3003.10, not as a vitamin under Chapter Heading 2936.00. 2. The appellant argued that 'caloshell' contains calcium carbonate and vitamin D3, approved by the Food and Drugs Authority for pediatric use, meeting the definition of a drug under the Drug and Cosmetics Act, 1940. 3. The appellant referenced the Indian Pharmacopoeia 1996 to establish the equivalence of 40000 units to 1 mg and the recommended dosage for the product. 4. The appellant relied on various judicial decisions to support the classification of similar products as medicaments under Chapter 30. 5. The Department argued that 'caloshell' lacks therapeutic or prophylactic value as it does not cure any disease, and therefore should be classified as a vitamin under Heading 2936.00. 6. The Department contended that the product's ingredients, calcium carbonate, and vitamin D3, do not individually have therapeutic value. 7. The Tribunal noted that 'caloshell' is licensed as a drug under the Drug and Cosmetics Act, 1940, and is intended to cure deficiencies of calcium and vitamin D in children, specifically for treating rickets. 8. The Tribunal referenced a previous case involving a similar product, holding it as a medicament, and cited other tribunal decisions classifying vitamins in capsule form as medicaments. 9. The Tribunal concluded that even if 'caloshell' is considered a vitamin, due to its measured doses, physician prescription, and FDA approval as a drug, it should be classified as a medicament under Chapter Heading 3003.10. 10. The Tribunal set aside the Commissioner (Appeals) order and allowed the appeal, classifying 'caloshell' as a medicament under Chapter Heading 3003.10.
This detailed analysis of the judgment provides a comprehensive understanding of the classification issue and the reasoning behind the decision to classify the product 'caloshell' as a medicament under Chapter Heading 3003.10.
Full Summary is available for active users!
Note: It is a system-generated summary and is for quick reference only.